Atara Biotherapeutics, Inc. (ATRA) 10-Year Financial Performance & Capital Metrics

ATRA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutAtara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.Show more

Revenue $129M +1404.0%
EBITDA -$78M +71.1%
Net Income -$85M +69.1%
EPS (Diluted) -11.41 +82.5%
Gross Margin 83.71% +2392.7%
EBITDA Margin -60.79% +98.1%
Operating Margin -64.71% +98.0%
Net Margin -66.23% +97.9%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -18.08 +65.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Efficient asset utilization: 1.2x turnover

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 6 (bottom 6%)
✗Shares diluted 76.8% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y85.07%

TTM51.27%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM117.57%

EPS CAGR

10Y-

5Y-

3Y-

TTM108.5%

ROCE

10Y Avg-77.81%

5Y Avg-102.94%

3Y Avg-128.55%

Latest-

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	20.34M	63.57M	8.57M	128.94M
Revenue Growth %	-	-	-	-	-	-	-	2.13%	-0.87%	14.04%
Cost of Goods Sold+	48K	383K	956K	3.78M	0	244.65M	282M	0	8.89M	21.01M
COGS % of Revenue	-	-	-	-	-	-	13.86%	-	1.04%	0.16%
Gross Profit+	-48K	-383K	-956K	-3.78M	0	-244.65M	-261.66M	63.57M	-313K	107.93M
Gross Margin %	-	-	-	-	-	-	-12.86%	1%	-0.04%	0.84%
Gross Profit Growth %	-	-6.98%	-1.5%	-2.96%	1%	-	-0.07%	1.24%	-1%	345.83%
Operating Expenses+	58.45M	81.24M	121.53M	237.11M	295.68M	64.4M	78.8M	344.09M	275.69M	191.37M
OpEx % of Revenue	-	-	-	-	-	-	3.87%	5.41%	32.16%	1.48%
Selling, General & Admin	16.83M	24.73M	40.33M	69.65M	79.58M	64.4M	78.8M	71.55M	50.91M	39.89M
SG&A % of Revenue	-	-	-	-	-	-	3.87%	1.13%	5.94%	0.31%
Research & Development	41.62M	56.51M	81.21M	167.46M	216.1M	244.65M	282M	272.53M	224.78M	151.48M
R&D % of Revenue	-	-	-	-	-	-	13.86%	4.29%	26.22%	1.17%
Other Operating Expenses	0	0	0	0	0	-244.65M	-282M	0	0	0
Operating Income+	-58.45M	-81.24M	-121.53M	-237.11M	-295.68M	-309.05M	-340.46M	-280.51M	-276.01M	-83.44M
Operating Margin %	-	-	-	-	-	-	-16.74%	-4.41%	-32.19%	-0.65%
Operating Income Growth %	-1.08%	-0.39%	-0.5%	-0.95%	-0.25%	-0.05%	-0.1%	0.18%	0.02%	0.7%
EBITDA+	-58.4M	-80.86M	-120.58M	-233.33M	-288.54M	-300.72M	-331.12M	-274.86M	-271.18M	-78.39M
EBITDA Margin %	-	-	-	-	-	-	-16.28%	-4.32%	-31.63%	-0.61%
EBITDA Growth %	-1.07%	-0.38%	-0.49%	-0.94%	-0.24%	-0.04%	-0.1%	0.17%	0.01%	0.71%
D&A (Non-Cash Add-back)	48K	383K	956K	3.78M	7.14M	8.33M	9.35M	5.65M	4.83M	5.05M
EBIT	-58.45M	-81.24M	-121.53M	-237.11M	-295.68M	-309.05M	-340.46M	-227.92M	-270.83M	-80.8M
Net Interest Income+	0	0	0	0	0	0	367K	2.69M	141K	-2.5M
Interest Income	1.22M	2.2M	2.03M	6.37M	0	0	367K	3.06M	5.43M	2.11M
Interest Expense	0	0	0	0	0	0	0	373K	5.29M	4.62M
Other Income/Expense	1.22M	2.2M	2.03M	6.37M	4.72M	2.45M	367K	52.22M	-105K	-1.98M
Pretax Income+	-57.23M	-79.04M	-119.5M	-230.74M	-290.96M	-306.61M	-340.1M	-228.29M	-276.11M	-85.42M
Pretax Margin %	-	-	-	-	-	-	-16.72%	-3.59%	-32.21%	-0.66%
Income Tax+	-9K	10K	-14K	-44K	12K	15K	46K	12K	15K	-12K
Effective Tax Rate %	10%	10%	10%	10%	1%	1%	1%	1%	1%	1%
Net Income+	-572.21M	-790.49M	-1.19B	-2.31B	-290.98M	-306.62M	-340.14M	-228.3M	-276.13M	-85.4M
Net Margin %	-	-	-	-	-	-	-16.72%	-3.59%	-32.21%	-0.66%
Net Income Growth %	-1.04%	-0.38%	-0.51%	-0.93%	0.87%	-0.05%	-0.11%	0.33%	-0.21%	0.69%
Net Income (Continuing)	-57.22M	-79.05M	-119.49M	-230.7M	-290.98M	-306.62M	-340.14M	-228.3M	-276.13M	-85.4M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-55.92	-68.78	-100.03	-131.64	-141.78	-103.63	-90.78	-55.96	-65.18	-11.41
EPS Growth %	0.6%	-0.23%	-0.45%	-0.32%	-0.08%	0.27%	0.12%	0.38%	-0.16%	0.82%
EPS (Basic)	-55.92	-68.78	-100.03	-131.64	-141.78	-103.63	-90.78	-55.96	-65.18	-11.41
Diluted Shares Outstanding	1.02M	1.15M	1.19M	1.75M	2.05M	2.96M	3.75M	4.08M	4.24M	7.49M
Basic Shares Outstanding	1.02M	1.15M	1.19M	1.75M	2.05M	2.96M	3.75M	4.08M	4.24M	7.49M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	324.6M	260.55M	172.19M	321.49M	272.99M	523.27M	384.62M	295.08M	101.87M	64.89M
Cash & Short-Term Investments	320.48M	255.68M	166.1M	309.63M	259.11M	500.66M	371.07M	242.82M	51.73M	42.5M
Cash Only	23.75M	47.97M	79.22M	60.7M	74.32M	200.4M	106.08M	92.94M	25.84M	25.03M
Short-Term Investments	296.74M	207.71M	86.87M	248.93M	184.79M	300.25M	264.98M	149.88M	25.88M	17.47M
Accounts Receivable	0	0	0	0	0	1.25M	986K	40.22M	34.11M	1.48M
Days Sales Outstanding	-	-	-	-	-	-	17.69	230.93	1.45K	4.2
Inventory	0	0	0	0	0	0	0	1.59M	9.71M	10.65M
Days Inventory Outstanding	-	-	-	-	-	-	-	-	398.68	185.11
Other Current Assets	194K	194K	194K	194K	194K	194K	194K	10.45M	6.33M	10.26M
Total Non-Current Assets+	378K	3.36M	45.59M	70.35M	69.95M	64.85M	83.51M	81.34M	63.63M	44.2M
Property, Plant & Equipment	270K	3.26M	44.13M	68.58M	68.18M	62.82M	79.94M	74.32M	58.79M	41.1M
Fixed Asset Turnover	-	-	-	-	-	-	0.25x	0.86x	0.15x	3.14x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	1.2M	0	0	0	0	0	0
Other Non-Current Assets	108K	102K	1.46M	574K	1.77M	2.03M	3.57M	7.02M	4.84M	3.1M
Total Assets+	324.98M	263.91M	217.78M	391.84M	342.94M	588.12M	468.13M	376.42M	165.5M	109.1M
Asset Turnover	-	-	-	-	-	-	0.04x	0.17x	0.05x	1.18x
Asset Growth %	2.06%	-0.19%	-0.17%	0.8%	-0.12%	0.71%	-0.2%	-0.2%	-0.56%	-0.34%
Total Current Liabilities+	9.71M	9.68M	27.65M	39.98M	36.74M	82.9M	105.79M	78.92M	142.23M	134.57M
Accounts Payable	1.45M	2.78M	14.71M	3.72M	7.96M	7.12M	17.37M	6.87M	3.68M	4.37M
Days Payables Outstanding	10.99K	2.65K	5.62K	359.01	-	10.62	22.48	-	151.32	75.87
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	-490K	0	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	0	0	500K	0	14.71M	19.89M	25.15M	32.75M	37.01M	6.59M
Current Ratio	33.43x	26.93x	6.23x	8.04x	7.43x	6.31x	3.64x	3.74x	0.72x	0.48x
Quick Ratio	33.43x	26.93x	6.23x	8.04x	7.43x	6.31x	3.64x	3.72x	0.65x	0.40x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	1.7K	113.44
Total Non-Current Liabilities+	166K	503K	12.27M	13M	15.42M	42.88M	82.73M	170.86M	122.51M	71.81M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	14.14M	13.04M	25.52M	58.06M	45.69M	29.91M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	166K	503K	12.27M	13M	1.28M	2.04M	1.5M	35.8M	39.25M	41.89M
Total Liabilities	9.88M	10.18M	39.91M	52.98M	52.16M	125.78M	188.51M	249.78M	264.74M	206.38M
Total Debt+	0	0	0	738K	15.72M	15.03M	28.27M	71.7M	57.87M	43.83M
Net Debt	-23.75M	-47.97M	-79.22M	-59.96M	-58.6M	-185.38M	-77.81M	-21.24M	32.03M	18.8M
Debt / Equity	-	-	-	0.00x	0.05x	0.03x	0.10x	0.57x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-752.05x	-52.22x	-18.08x
Total Equity+	315.1M	253.74M	177.86M	338.86M	290.78M	462.34M	279.61M	126.64M	-99.23M	-97.28M
Equity Growth %	2.05%	-0.19%	-0.3%	0.91%	-0.14%	0.59%	-0.4%	-0.55%	-1.78%	0.02%
Book Value per Share	307.92	220.78	148.90	193.36	141.68	156.25	74.63	31.04	-23.42	-12.99
Total Shareholders' Equity	315.1M	253.74M	177.86M	338.86M	290.78M	462.34M	279.61M	126.64M	-99.23M	-97.28M
Common Stock	3K	3K	3K	5K	6K	8K	9K	10K	11K	1K
Retained Earnings	-98.11M	-177.16M	-296.65M	-527.35M	-817.96M	-1.12B	-1.46B	-1.69B	-1.97B	-2.05B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-518K	-183K	-151K	-340K	220K	296K	-368K	-2.07M	-204K	8K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-37.16M	-60.02M	-87.5M	-179.77M	-235.63M	-180.76M	-220.52M	-270.43M	-192.98M	-68.72M
Operating CF Margin %	-	-	-	-	-	-	-10.84%	-4.25%	-22.51%	-0.53%
Operating CF Growth %	-1.23%	-0.62%	-0.46%	-1.05%	-0.31%	0.23%	-0.22%	-0.23%	0.29%	0.64%
Net Income	-57.22M	-79.05M	-119.49M	-230.7M	-290.98M	-306.62M	-340.14M	-228.3M	-276.13M	-85.4M
Depreciation & Amortization	48K	383K	956K	3.73M	7.07M	8.33M	9.35M	5.65M	4.83M	5.05M
Stock-Based Compensation	10.25M	16.78M	23.1M	33.82M	51.7M	51.35M	53.87M	53.84M	45.39M	27M
Deferred Taxes	0	0	0	-1.89M	0	958K	1.79M	0	0	0
Other Non-Cash Items	3.58M	2.58M	732K	260K	732K	1.53M	2.04M	-40.15M	17.59M	15.59M
Working Capital Changes	6.19M	-725K	7.2M	15M	-4.15M	63.69M	52.58M	-61.47M	15.34M	-30.96M
Change in Receivables	0	0	0	0	0	-1.25M	264K	-39.23M	6.11M	32.63M
Change in Inventory	0	0	0	0	0	-1.25M	3.34M	-1.59M	-8.12M	-4.43M
Change in Payables	1M	981K	2.16M	-1.96M	4.21M	-815K	9.07M	-9.21M	-3.13M	687K
Cash from Investing+	-220.13M	83.74M	98.71M	-196.29M	60.46M	-120.73M	22.26M	202.96M	123.87M	8.62M
Capital Expenditures	-290K	-3.02M	-20.23M	-35.92M	-5.73M	-4.51M	-10.58M	-4.19M	-1.22M	-246K
CapEx % of Revenue	-	-	-	-	-	-	0.52%	0.07%	0.14%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-194K	83.74M	-1.2M	-160.36M	161K	-116.22M	32.84M	94.77M	25K	0
Cash from Financing+	259.23M	506K	20.05M	357.54M	188.79M	427.57M	103.94M	53.08M	2.01M	59.28M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-4.21M	506K	892K	17.19M	655K	4.99M	5.5M	31.71M	821K	223K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-37.45M	-63.05M	-107.73M	-215.7M	-241.36M	-185.27M	-231.1M	-274.62M	-194.2M	-68.96M
FCF Margin %	-	-	-	-	-	-	-11.36%	-4.32%	-22.65%	-0.53%
FCF Growth %	-1.25%	-0.68%	-0.71%	-1%	-0.12%	0.23%	-0.25%	-0.19%	0.29%	0.64%
FCF per Share	-36.59	-54.86	-90.19	-123.08	-117.60	-62.61	-61.68	-67.32	-45.84	-9.21
FCF Conversion (FCF/Net Income)	0.06x	0.08x	0.07x	0.08x	0.81x	0.59x	0.65x	1.18x	0.70x	0.80x
Interest Paid	0	0	0	0	50K	62K	32K	335K	447K	685K
Taxes Paid	3K	10K	0	0	0	10K	15K	19K	2K	24K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-273.6%	-277.93%	-553.71%	-892.93%	-92.43%	-81.43%	-91.69%	-112.39%	-2014.86%	-
Return on Invested Capital (ROIC)	-23.53%	-24.51%	-59.89%	-94.21%	-86.78%	-91.05%	-106.67%	-136.97%	-1083.74%	-
Gross Margin	-	-	-	-	-	-	-1286.44%	100%	-3.65%	83.71%
Net Margin	-	-	-	-	-	-	-1672.28%	-359.12%	-3220.88%	-66.23%
Debt / Equity	-	-	-	0.00x	0.05x	0.03x	0.10x	0.57x	-	-
Interest Coverage	-	-	-	-	-	-	-	-752.05x	-52.22x	-18.08x
FCF Conversion	0.06x	0.08x	0.07x	0.08x	0.81x	0.59x	0.65x	1.18x	0.70x	0.80x
Revenue Growth	-	-	-	-	-	-	-	212.55%	-86.51%	1404.02%

Frequently Asked Questions

Growth & Financials

Atara Biotherapeutics, Inc. (ATRA) reported $151.9M in revenue for fiscal year 2024.

Atara Biotherapeutics, Inc. (ATRA) grew revenue by 1404.0% over the past year. This is strong growth.

Yes, Atara Biotherapeutics, Inc. (ATRA) is profitable, generating $23.4M in net income for fiscal year 2024 (-66.2% net margin).

Dividend & Returns

Atara Biotherapeutics, Inc. (ATRA) had negative free cash flow of $69.8M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Atara Biotherapeutics, Inc. (ATRA) 10-Year Financial Performance & Capital Metrics

ATRA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $129M +1404.0%
EBITDA -$78M +71.1%
Net Income -$85M +69.1%
EPS (Diluted) -11.41 +82.5%
Gross Margin 83.71% +2392.7%
EBITDA Margin -60.79% +98.1%
Operating Margin -64.71% +98.0%
Net Margin -66.23% +97.9%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -18.08 +65.4%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Efficient asset utilization: 1.2x turnover

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 6 (bottom 6%)
✗Shares diluted 76.8% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y85.07%

TTM51.27%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM117.57%

EPS CAGR

10Y-

5Y-

3Y-

TTM108.5%

ROCE

10Y Avg-77.81%

5Y Avg-102.94%

3Y Avg-128.55%

Latest-

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	20.34M	63.57M	8.57M	128.94M
Revenue Growth %	-	-	-	-	-	-	-	2.13%	-0.87%	14.04%
Cost of Goods Sold+	48K	383K	956K	3.78M	0	244.65M	282M	0	8.89M	21.01M
COGS % of Revenue	-	-	-	-	-	-	13.86%	-	1.04%	0.16%
Gross Profit+	-48K	-383K	-956K	-3.78M	0	-244.65M	-261.66M	63.57M	-313K	107.93M
Gross Margin %	-	-	-	-	-	-	-12.86%	1%	-0.04%	0.84%
Gross Profit Growth %	-	-6.98%	-1.5%	-2.96%	1%	-	-0.07%	1.24%	-1%	345.83%
Operating Expenses+	58.45M	81.24M	121.53M	237.11M	295.68M	64.4M	78.8M	344.09M	275.69M	191.37M
OpEx % of Revenue	-	-	-	-	-	-	3.87%	5.41%	32.16%	1.48%
Selling, General & Admin	16.83M	24.73M	40.33M	69.65M	79.58M	64.4M	78.8M	71.55M	50.91M	39.89M
SG&A % of Revenue	-	-	-	-	-	-	3.87%	1.13%	5.94%	0.31%
Research & Development	41.62M	56.51M	81.21M	167.46M	216.1M	244.65M	282M	272.53M	224.78M	151.48M
R&D % of Revenue	-	-	-	-	-	-	13.86%	4.29%	26.22%	1.17%
Other Operating Expenses	0	0	0	0	0	-244.65M	-282M	0	0	0
Operating Income+	-58.45M	-81.24M	-121.53M	-237.11M	-295.68M	-309.05M	-340.46M	-280.51M	-276.01M	-83.44M
Operating Margin %	-	-	-	-	-	-	-16.74%	-4.41%	-32.19%	-0.65%
Operating Income Growth %	-1.08%	-0.39%	-0.5%	-0.95%	-0.25%	-0.05%	-0.1%	0.18%	0.02%	0.7%
EBITDA+	-58.4M	-80.86M	-120.58M	-233.33M	-288.54M	-300.72M	-331.12M	-274.86M	-271.18M	-78.39M
EBITDA Margin %	-	-	-	-	-	-	-16.28%	-4.32%	-31.63%	-0.61%
EBITDA Growth %	-1.07%	-0.38%	-0.49%	-0.94%	-0.24%	-0.04%	-0.1%	0.17%	0.01%	0.71%
D&A (Non-Cash Add-back)	48K	383K	956K	3.78M	7.14M	8.33M	9.35M	5.65M	4.83M	5.05M
EBIT	-58.45M	-81.24M	-121.53M	-237.11M	-295.68M	-309.05M	-340.46M	-227.92M	-270.83M	-80.8M
Net Interest Income+	0	0	0	0	0	0	367K	2.69M	141K	-2.5M
Interest Income	1.22M	2.2M	2.03M	6.37M	0	0	367K	3.06M	5.43M	2.11M
Interest Expense	0	0	0	0	0	0	0	373K	5.29M	4.62M
Other Income/Expense	1.22M	2.2M	2.03M	6.37M	4.72M	2.45M	367K	52.22M	-105K	-1.98M
Pretax Income+	-57.23M	-79.04M	-119.5M	-230.74M	-290.96M	-306.61M	-340.1M	-228.29M	-276.11M	-85.42M
Pretax Margin %	-	-	-	-	-	-	-16.72%	-3.59%	-32.21%	-0.66%
Income Tax+	-9K	10K	-14K	-44K	12K	15K	46K	12K	15K	-12K
Effective Tax Rate %	10%	10%	10%	10%	1%	1%	1%	1%	1%	1%
Net Income+	-572.21M	-790.49M	-1.19B	-2.31B	-290.98M	-306.62M	-340.14M	-228.3M	-276.13M	-85.4M
Net Margin %	-	-	-	-	-	-	-16.72%	-3.59%	-32.21%	-0.66%
Net Income Growth %	-1.04%	-0.38%	-0.51%	-0.93%	0.87%	-0.05%	-0.11%	0.33%	-0.21%	0.69%
Net Income (Continuing)	-57.22M	-79.05M	-119.49M	-230.7M	-290.98M	-306.62M	-340.14M	-228.3M	-276.13M	-85.4M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-55.92	-68.78	-100.03	-131.64	-141.78	-103.63	-90.78	-55.96	-65.18	-11.41
EPS Growth %	0.6%	-0.23%	-0.45%	-0.32%	-0.08%	0.27%	0.12%	0.38%	-0.16%	0.82%
EPS (Basic)	-55.92	-68.78	-100.03	-131.64	-141.78	-103.63	-90.78	-55.96	-65.18	-11.41
Diluted Shares Outstanding	1.02M	1.15M	1.19M	1.75M	2.05M	2.96M	3.75M	4.08M	4.24M	7.49M
Basic Shares Outstanding	1.02M	1.15M	1.19M	1.75M	2.05M	2.96M	3.75M	4.08M	4.24M	7.49M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	324.6M	260.55M	172.19M	321.49M	272.99M	523.27M	384.62M	295.08M	101.87M	64.89M
Cash & Short-Term Investments	320.48M	255.68M	166.1M	309.63M	259.11M	500.66M	371.07M	242.82M	51.73M	42.5M
Cash Only	23.75M	47.97M	79.22M	60.7M	74.32M	200.4M	106.08M	92.94M	25.84M	25.03M
Short-Term Investments	296.74M	207.71M	86.87M	248.93M	184.79M	300.25M	264.98M	149.88M	25.88M	17.47M
Accounts Receivable	0	0	0	0	0	1.25M	986K	40.22M	34.11M	1.48M
Days Sales Outstanding	-	-	-	-	-	-	17.69	230.93	1.45K	4.2
Inventory	0	0	0	0	0	0	0	1.59M	9.71M	10.65M
Days Inventory Outstanding	-	-	-	-	-	-	-	-	398.68	185.11
Other Current Assets	194K	194K	194K	194K	194K	194K	194K	10.45M	6.33M	10.26M
Total Non-Current Assets+	378K	3.36M	45.59M	70.35M	69.95M	64.85M	83.51M	81.34M	63.63M	44.2M
Property, Plant & Equipment	270K	3.26M	44.13M	68.58M	68.18M	62.82M	79.94M	74.32M	58.79M	41.1M
Fixed Asset Turnover	-	-	-	-	-	-	0.25x	0.86x	0.15x	3.14x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	1.2M	0	0	0	0	0	0
Other Non-Current Assets	108K	102K	1.46M	574K	1.77M	2.03M	3.57M	7.02M	4.84M	3.1M
Total Assets+	324.98M	263.91M	217.78M	391.84M	342.94M	588.12M	468.13M	376.42M	165.5M	109.1M
Asset Turnover	-	-	-	-	-	-	0.04x	0.17x	0.05x	1.18x
Asset Growth %	2.06%	-0.19%	-0.17%	0.8%	-0.12%	0.71%	-0.2%	-0.2%	-0.56%	-0.34%
Total Current Liabilities+	9.71M	9.68M	27.65M	39.98M	36.74M	82.9M	105.79M	78.92M	142.23M	134.57M
Accounts Payable	1.45M	2.78M	14.71M	3.72M	7.96M	7.12M	17.37M	6.87M	3.68M	4.37M
Days Payables Outstanding	10.99K	2.65K	5.62K	359.01	-	10.62	22.48	-	151.32	75.87
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	-490K	0	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	0	0	500K	0	14.71M	19.89M	25.15M	32.75M	37.01M	6.59M
Current Ratio	33.43x	26.93x	6.23x	8.04x	7.43x	6.31x	3.64x	3.74x	0.72x	0.48x
Quick Ratio	33.43x	26.93x	6.23x	8.04x	7.43x	6.31x	3.64x	3.72x	0.65x	0.40x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	1.7K	113.44
Total Non-Current Liabilities+	166K	503K	12.27M	13M	15.42M	42.88M	82.73M	170.86M	122.51M	71.81M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	14.14M	13.04M	25.52M	58.06M	45.69M	29.91M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	166K	503K	12.27M	13M	1.28M	2.04M	1.5M	35.8M	39.25M	41.89M
Total Liabilities	9.88M	10.18M	39.91M	52.98M	52.16M	125.78M	188.51M	249.78M	264.74M	206.38M
Total Debt+	0	0	0	738K	15.72M	15.03M	28.27M	71.7M	57.87M	43.83M
Net Debt	-23.75M	-47.97M	-79.22M	-59.96M	-58.6M	-185.38M	-77.81M	-21.24M	32.03M	18.8M
Debt / Equity	-	-	-	0.00x	0.05x	0.03x	0.10x	0.57x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-752.05x	-52.22x	-18.08x
Total Equity+	315.1M	253.74M	177.86M	338.86M	290.78M	462.34M	279.61M	126.64M	-99.23M	-97.28M
Equity Growth %	2.05%	-0.19%	-0.3%	0.91%	-0.14%	0.59%	-0.4%	-0.55%	-1.78%	0.02%
Book Value per Share	307.92	220.78	148.90	193.36	141.68	156.25	74.63	31.04	-23.42	-12.99
Total Shareholders' Equity	315.1M	253.74M	177.86M	338.86M	290.78M	462.34M	279.61M	126.64M	-99.23M	-97.28M
Common Stock	3K	3K	3K	5K	6K	8K	9K	10K	11K	1K
Retained Earnings	-98.11M	-177.16M	-296.65M	-527.35M	-817.96M	-1.12B	-1.46B	-1.69B	-1.97B	-2.05B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-518K	-183K	-151K	-340K	220K	296K	-368K	-2.07M	-204K	8K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-37.16M	-60.02M	-87.5M	-179.77M	-235.63M	-180.76M	-220.52M	-270.43M	-192.98M	-68.72M
Operating CF Margin %	-	-	-	-	-	-	-10.84%	-4.25%	-22.51%	-0.53%
Operating CF Growth %	-1.23%	-0.62%	-0.46%	-1.05%	-0.31%	0.23%	-0.22%	-0.23%	0.29%	0.64%
Net Income	-57.22M	-79.05M	-119.49M	-230.7M	-290.98M	-306.62M	-340.14M	-228.3M	-276.13M	-85.4M
Depreciation & Amortization	48K	383K	956K	3.73M	7.07M	8.33M	9.35M	5.65M	4.83M	5.05M
Stock-Based Compensation	10.25M	16.78M	23.1M	33.82M	51.7M	51.35M	53.87M	53.84M	45.39M	27M
Deferred Taxes	0	0	0	-1.89M	0	958K	1.79M	0	0	0
Other Non-Cash Items	3.58M	2.58M	732K	260K	732K	1.53M	2.04M	-40.15M	17.59M	15.59M
Working Capital Changes	6.19M	-725K	7.2M	15M	-4.15M	63.69M	52.58M	-61.47M	15.34M	-30.96M
Change in Receivables	0	0	0	0	0	-1.25M	264K	-39.23M	6.11M	32.63M
Change in Inventory	0	0	0	0	0	-1.25M	3.34M	-1.59M	-8.12M	-4.43M
Change in Payables	1M	981K	2.16M	-1.96M	4.21M	-815K	9.07M	-9.21M	-3.13M	687K
Cash from Investing+	-220.13M	83.74M	98.71M	-196.29M	60.46M	-120.73M	22.26M	202.96M	123.87M	8.62M
Capital Expenditures	-290K	-3.02M	-20.23M	-35.92M	-5.73M	-4.51M	-10.58M	-4.19M	-1.22M	-246K
CapEx % of Revenue	-	-	-	-	-	-	0.52%	0.07%	0.14%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-194K	83.74M	-1.2M	-160.36M	161K	-116.22M	32.84M	94.77M	25K	0
Cash from Financing+	259.23M	506K	20.05M	357.54M	188.79M	427.57M	103.94M	53.08M	2.01M	59.28M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-4.21M	506K	892K	17.19M	655K	4.99M	5.5M	31.71M	821K	223K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-37.45M	-63.05M	-107.73M	-215.7M	-241.36M	-185.27M	-231.1M	-274.62M	-194.2M	-68.96M
FCF Margin %	-	-	-	-	-	-	-11.36%	-4.32%	-22.65%	-0.53%
FCF Growth %	-1.25%	-0.68%	-0.71%	-1%	-0.12%	0.23%	-0.25%	-0.19%	0.29%	0.64%
FCF per Share	-36.59	-54.86	-90.19	-123.08	-117.60	-62.61	-61.68	-67.32	-45.84	-9.21
FCF Conversion (FCF/Net Income)	0.06x	0.08x	0.07x	0.08x	0.81x	0.59x	0.65x	1.18x	0.70x	0.80x
Interest Paid	0	0	0	0	50K	62K	32K	335K	447K	685K
Taxes Paid	3K	10K	0	0	0	10K	15K	19K	2K	24K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-273.6%	-277.93%	-553.71%	-892.93%	-92.43%	-81.43%	-91.69%	-112.39%	-2014.86%	-
Return on Invested Capital (ROIC)	-23.53%	-24.51%	-59.89%	-94.21%	-86.78%	-91.05%	-106.67%	-136.97%	-1083.74%	-
Gross Margin	-	-	-	-	-	-	-1286.44%	100%	-3.65%	83.71%
Net Margin	-	-	-	-	-	-	-1672.28%	-359.12%	-3220.88%	-66.23%
Debt / Equity	-	-	-	0.00x	0.05x	0.03x	0.10x	0.57x	-	-
Interest Coverage	-	-	-	-	-	-	-	-752.05x	-52.22x	-18.08x
FCF Conversion	0.06x	0.08x	0.07x	0.08x	0.81x	0.59x	0.65x	1.18x	0.70x	0.80x
Revenue Growth	-	-	-	-	-	-	-	212.55%	-86.51%	1404.02%

Frequently Asked Questions

Growth & Financials

Atara Biotherapeutics, Inc. (ATRA) reported $151.9M in revenue for fiscal year 2024.

Atara Biotherapeutics, Inc. (ATRA) grew revenue by 1404.0% over the past year. This is strong growth.

Yes, Atara Biotherapeutics, Inc. (ATRA) is profitable, generating $23.4M in net income for fiscal year 2024 (-66.2% net margin).

Dividend & Returns

Atara Biotherapeutics, Inc. (ATRA) had negative free cash flow of $69.8M in fiscal year 2024, likely due to heavy capital investments.